These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11163671)

  • 41. [Swine erysipelas: from yesterday to today].
    Akkermans JP
    Tijdschr Diergeneeskd; 1987 Apr; 112(8):451-60. PubMed ID: 3554608
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of an enzyme-linked immunosorbent assay for potency testing of erysipelas bacterins.
    Henderson LM; Scheevel KF; Walden DM
    Dev Biol Stand; 1996; 86():333. PubMed ID: 8785973
    [No Abstract]   [Full Text] [Related]  

  • 43. [Comparative effectiveness of vaccines against erysipelas].
    Koniaev MT; Shcherbinin VK
    Veterinariia; 1980 Mar; (3):33-4. PubMed ID: 7395054
    [No Abstract]   [Full Text] [Related]  

  • 44. Potency testing of inactivated erysipelas vaccines by ELISA--influence of the adjuvant on antibody development.
    Rosskopf-Streicher U; Johannes S; Cussler K
    Dev Biol (Basel); 2002; 111():159-62. PubMed ID: 12678236
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development and prevalidation of two different ELISA systems for the potency testing of Clostridium perfringens beta and epsilon-toxoid containing veterinary vaccines.
    Ebert E; Oppling V; Werner E; Cussler K
    FEMS Immunol Med Microbiol; 1999 Jul; 24(3):299-311. PubMed ID: 10397315
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Collaborative study for the establishment of the Ph. Eur. BRP batch 1 for anti-vaccinia immunoglobulin.
    Fuchs F; Poirier B; Leparc-Goffart I; Buchheit KH
    Pharmeuropa Bio; 2005 Sep; 2005(1):13-8. PubMed ID: 16336934
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of Erysipelothrix rhusiopathiae vaccines in pigs by intradermal challenge and immune responses.
    Eamens GJ; Chin JC; Turner B; Barchia I
    Vet Microbiol; 2006 Aug; 116(1-3):138-48. PubMed ID: 16678363
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Establishment of European Pharmacopoeia BRP batch 2 for inactivated poliomyelitis vaccine for in vitro D antigen assay.
    Fuchs F; Minor P; Daas A; Milne C
    Pharmeuropa Bio; 2003 Jul; 2003(1):23-50. PubMed ID: 14563307
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Establishment of European Pharmacopoeia (Ph. Eur.) Biological Reference Preparations (BRP) batch 2 for rDNA hepatitis B vaccine (method A and B).
    Dobbelaer R; Daas A; Milne C
    Pharmeuropa Bio; 2004 Jan; 2003(2):77-90. PubMed ID: 14960264
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Onset and duration of immunity following aerogenic immunization of swine against swine pest and erysipelas].
    Kaden V; Heller P; Polster U; Glaner M
    Arch Exp Veterinarmed; 1985 Sep; 39(5):730-7. PubMed ID: 4074082
    [No Abstract]   [Full Text] [Related]  

  • 51. [Comparative investigations of a combined vaccine against parvovirus and erysipelas and corresponding monovaccines in different vaccination schedules. 1: Field trial].
    Ritzmann M; Gerbermann H; Gyra H; Eichinger HM; Heinritzi K
    Tierarztl Prax Ausg G Grosstiere Nutztiere; 1999 May; 27(3):168-74. PubMed ID: 10384706
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Collaborative study for the validation of alternative in vitro potency assays for human tetanus immunoglobulin.
    Gross S; Janssen SW; de Vries B; Terao E; Daas A; Buchheit KH
    Pharmeur Bio Sci Notes; 2009 Oct; 2009(1):11-25. PubMed ID: 20144449
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Study on hog cholera-sine erysipelas combined liver vaccine. I. Experimental preparation of combined live vaccine (author's transl)].
    Eto M; Susumi S; Mishima M; Kobori N; Watanabe S
    Igaku Kenkyu; 1980 Aug; 50(6):490-4. PubMed ID: 7304106
    [No Abstract]   [Full Text] [Related]  

  • 54. European Pharmacopoeia biological reference preparation for poliomyelitis vaccine (inactivated): collaborative study for the establishment of batch No. 3.
    Martin J; Daas A; Milne C
    Pharmeur Bio Sci Notes; 2016; 2016():135-150. PubMed ID: 28279255
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Feasibility study to evaluate the correlation between results of a candidate in vitro assay and established in vivo assays for potency determination of Newcastle disease vaccines.
    Claassen I; Maas R; Daas A; Milne C
    Pharmeuropa Bio; 2003 Jul; 2003(1):51-66. PubMed ID: 14563308
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Studies of the occurrence of erysipelas bacteria in healthy swine in the Hungarian People's Republic with reference to possible use of erysipelas live vaccines].
    Kucsera G
    Arch Exp Veterinarmed; 1980; 34(1):63-5. PubMed ID: 7416896
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines.
    Rooijakkers E; Groen J; Uittenbogarrd J; van Herwijnen J; Osterhaus A
    Dev Biol Stand; 1996; 86():137-45. PubMed ID: 8785943
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Collaborative study for the establishment of the Ph. Eur. BRP for oral poliomyelitis vaccine (OPV) Batch 3 for use in the potency assay.
    Buchheit KH; Daas A; Stalder J
    Pharmeuropa Spec Issue Biol; 2002 Jun; 2002(1):67-91. PubMed ID: 12448032
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serological assays as alternatives to the Ph Eur challenge test for batch release of tetanus vaccines for human use.
    Winsnes R; Hendriksen C; Sesardic D; Akkermans A; Daas A
    Dev Biol Stand; 1999; 101():277-88. PubMed ID: 10566802
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral vaccination against swine erysipelas--field experiences in Croatia.
    Hoffmann CR; Bilkei G
    Dtsch Tierarztl Wochenschr; 2006 Jan; 113(1):13-5. PubMed ID: 16475549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.